Rabbit anti Human Proprotein convertase subtilisin/kexin type 9 (PCSK9), NARC1

Rabbit anti Human Proprotein convertase subtilisin/kexin type 9 (PCSK9), NARC1

• Background: PCSK9 binds to the EGF-A domain of the LDLR and signals LDLR degradation. Reduced LDLR levels result in decreased LDL (low density lipid) metabolism leading to hypercholesterolemia. _x000B__x000B_Additioanlly, PCSK9 may be implicated in the differentiation of cortical neurons and may also play a role in cholesterol homeostasis. Defects in PCSK9 gene are the cause of familial hypercholesterolemia 3 (FH3). The protein is thought to play a central role in cholesterol homeostais. For an antibody that targets the blocking epitope of the PCSK-LDLR interaction use X2404P.
• Synonyms: ProProtein convertase PC9, Subtilisin/kexin-like protease PC9, Neural apoptosis-regulated convertase 1
• CAS Number: 9007-83-4
• UniProt: Q8NBP7
• Host: Rabbit
• Species Reactivity: Human
• Isotype: IgG
• Conjugation: Affinity Purified
• Type: Antigen Immunoaffinity Purified Polyclonal
• Applications: WB, ELISA
• Field of Research: Lipid Mediators
• Purification Method: Antigen Immunoaffiinity Purification
• Assay Principle: Antibody can be used for Western blotting (1:400 dilution) and immunocytochemistry (10 µg/mL). Optimal concentration should be evaluated by serial dilutions.
• Stability: See expiration date on vial
• Concentration: See vial for Concentration
• Form: Provided as solution in phosphate buffered saline with 0,08% sodium azide
• Precautions: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.
• References & Citations: 1. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33. Epub 2003 Jan 27. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Seidah NG, et al 2. Nat Genet. 2003 Jun;34(2):154-6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Abifadel et al 3. Hum Mutat. 2005 Nov;26(5):497. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Allard D et al 4. Am J Hum Genet. 2006 Mar;78(3):410-22. Epub 2006 Jan 20. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Kotowski IK, et al 5. Clin Genet. 2004 May;65(5):419-22. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Leren TP. 6. PLoS One. 2007 Oct 31;2(10):e1098. Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. Ding K, McDonough SJ, Kullo IJ. 7. J Hum Genet. 2004;49(2):109-14. Epub 2004 Jan 15. Genetic variants in PCSK9 affect the cholesterol level in Japanese. Shioji K, et al 8. Atherosclerosis. 2005 Oct;182(2):331-40. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Graham CA et al 9. Cell. 2006 Nov 3;127(3):635-48. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Olsen J V et al 10. J Am Coll Cardiol. 2005 May 17;45(10):1611-9. Epub 2005 Apr 21. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. Chen SN et al
• Shipping Conditions: Ambient Temperature, freeze upon arrival
• Storage Conditions: Product should be stored at -20ºC; Aliquot to avoid freeze/thaw cycles
• Functional Analysis: WB